Sanofi: positive data on chronic spontaneous urticaria

(CercleFinance.com) - Sanofi announces the presentation of new positive Phase III data in the treatment of chronic spontaneous urticaria at the ACAAI Congress.


The results of this study show that treatment with Dupixent significantly reduced pruritus and disease activity scores (itching and urticaria) compared with inclusion scores, and that urticaria was well controlled in a higher proportion of patients, compared with placebo. A good level of disease control was achieved in 41% of patients.

Confirmatory data will be submitted to support renewal of the regulatory application in the US by the end of the year. If approved, Dupixent will become the first new targeted drug for the treatment of chronic spontaneous urticaria in more than a decade.

In the US, more than 300,000 people have chronic spontaneous urticaria inadequately controlled by antihistamines.

Dr. Thomas B. Casale, Professor, Internal Medicine, Morsani School of Medicine, University of South Florida, USA said that Chronic spontaneous urticaria is an inflammatory skin disease characterized by the sudden onset of urticarial papules accompanied by intense itching, often with a severe impact on patients' quality of life. These data confirm the results obtained in the previous A study, and show once again that Dupixent has the potential to significantly relieve patients' symptoms and help them better control this distressing disease.


Copyright (c) 2024 CercleFinance.com. All rights reserved.